0001179110-19-006055.txt : 20190515
0001179110-19-006055.hdr.sgml : 20190515
20190515072144
ACCESSION NUMBER: 0001179110-19-006055
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190513
FILED AS OF DATE: 20190515
DATE AS OF CHANGE: 20190515
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Coleman Mark
CENTRAL INDEX KEY: 0001658379
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37635
FILM NUMBER: 19825066
MAIL ADDRESS:
STREET 1: 25 BROADWAY
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10004
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axsome Therapeutics, Inc.
CENTRAL INDEX KEY: 0001579428
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 454241907
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BROADWAY, 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10038
BUSINESS PHONE: (212) 332-3241
MAIL ADDRESS:
STREET 1: 200 BROADWAY, 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10038
4
1
edgar.xml
FORM 4 -
X0306
4
2019-05-13
0
0001579428
Axsome Therapeutics, Inc.
AXSM
0001658379
Coleman Mark
C/O AXSOME THERAPEUTICS, INC.
200 BROADWAY, 3RD FLOOR
NEW YORK
NY
10038
1
0
0
0
Common Stock
2019-05-13
4
P
0
4650
21.44
A
652648
D
Common Stock
5100
I
See Footnote
The price reported in Column 4 is an average price. These shares were purchased by the reporting person in multiple transactions at prices ranging from $21.42 to $21.49, inclusive. The reporting person undertakes to provide to Axsome Therapeutics, Inc., the staff of the Securities and Exchange Commission, and others pursuant to applicable securities laws, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (1) to this Form 4.
Represents additional shares held indirectly by the reporting person prior to May 13, 2019. See Footnote 3.
Such shares were purchased by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.
/s/ Mark Coleman
2019-05-15